Showing results (71-80 of 100) with videos related to
Sort By:
Pageof 10
Journal of Clinical Psychopharmacology|June 23, 2004
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidolJan Volavka, Pal Czobor, Karen Nolan, et al.The Journal of Clinical Psychiatry|May 4, 2004
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophreniaJean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, et al.The Journal of Clinical Psychiatry|March 7, 2019
Clinical Guidance on the Identification and Management of Treatment-Resistant SchizophreniaJohn M Kane, Ofer Agid, Marjorie L Baldwin, et al.The American Journal of Psychiatry|August 3, 2004
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trialMarc Bourgeois, Joel Swendsen, Frederick Young, et al.Psychiatry Research|November 10, 2017
Do cognitive deficits predict negative emotionality and aggression in schizophrenia?Anthony O Ahmed, Jenae Richardson, Alex Buckner, et al.American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|April 27, 2004
COMT158 polymorphism and hostilityJan Volavka, James L Kennedy, Xingqun Ni, et al.JAMA Psychiatry|March 3, 2021
Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysisKatsuhiko Hagi, Tadashi Nosaka, Dwight Dickinson, et al.Journal of Clinical Psychopharmacology|November 6, 2019
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive DyskinesiaStephen R Marder, Carlos Singer, Jean-Pierre Lindenmayer, et al.The Journal of Clinical Psychiatry|April 14, 2022
Phase 3b Multicenter, Prospective, Open-label Trial to Evaluate the Effects of a Digital Medicine System on Inpatient Psychiatric Hospitalization Rates for Adults With SchizophreniaElan A Cohen, Taisa Skubiak, Dusica Hadzi Boskovic, et al.Schizophrenia Bulletin|January 6, 2005
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patientsLarry Alphs, Ravi Anand, M Zahur Islam, et al.Pageof 10